In the prospective RxPONDER trial, which included 5018 women with HR positive, HER2 negative breast cancer, one to three positive axillary lymph nodes, and a recurrence score of 25 or lower, premenopausal women who received chemoendocrine therapy had longer invasive disease free survival and distant relapse free survival than those who received endocrine only therapy

مهمان عزیز شما حق دیدن لینک ها را ندارید برای استفاده از امکانات کامل انجمن عضو شوید

عضویت

Subchronic toxicity testing involved testing of a repeated dose for 90 days